1. In Vivo
  2. >>Deal-Making

In Vivo's Deals Of The Month, March 2017

 
• By Nancy Dvorin

Free article: In Vivo's editors pick March's most significant deals, including Spero's Series C and Allergan's deal with Editas.

IV_DOTM_1200

Allergan PLC, not known for its interest in early-stage R&D,has obtained exclusive access and the option to license up to five of Editas Medicine Inc.'s genome-editing ophthalmic programs – including its lead program candidate for Leber congenital amaurosis, a rare, inherited retinal degenerative disease that appears in childhood and leads to blindness. Editas, which also closed an $84.6 million FOPO in March, gets $90 million up front from Allergan as well as potential milestone payments and royalties from any approved products. [See Deal]

Antibacterials developer Spero Therapeutics LLC raised $51.7 million in an oversubscribed Series C round led by first-time backer GV (formerly Google Ventures). GV was joined by other new investors...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.